Cardiovascular Events Associated With Use of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Population-Based Cohort Study.

@article{Dahln2016CardiovascularEA,
  title={Cardiovascular Events Associated With Use of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Population-Based Cohort Study.},
  author={Torsten Dahl{\'e}n and Gustaf Edgren and Mats Lambe and Mattias H{\"o}glund and Magnus Bj{\"o}rkholm and F. Carmo Sandin and Anders Sj{\"a}lander and Johan Richter and Ulla Olsson-Stroemberg and Lotta Ohm and Magnus B{\"a}ck and Gorgine de Greef},
  journal={Annals of internal medicine},
  year={2016},
  volume={165 3},
  pages={
          161-6
        }
}
BACKGROUND Tyrosine kinase inhibitors (TKIs) have increased survival dramatically for patients with chronic myeloid leukemia (CML), but continuous administration of these drugs may elicit long-term toxicity. OBJECTIVE To investigate the incidence of vascular events in patients with CML treated with first- and second-generation TKIs. DESIGN Retrospective cohort study using nationwide population-based registries. SETTING Sweden. PATIENTS All patients diagnosed with chronic-phase CML in… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 15 CITATIONS

Chronic myeloid leukemia and cancer

VIEW 11 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Cardiovascular Risk in Cancer Survivors

  • Current Treatment Options in Cardiovascular Medicine
  • 2018

References

Publications referenced by this paper.
SHOWING 1-10 OF 25 REFERENCES

Chronic myelogenous leukemia, version 1.2015.

  • Journal of the National Comprehensive Cancer Network : JNCCN
  • 2014
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

and Drug Administration

U. S. Foo
  • Drug Safety Communication: FDA requires multiple new safety measures for leukemia drug Iclusig; company expected to resume marketing. 31 October 2013 [updated 5 November 2013]. Accessed at www.fda.gov/Drugs /DrugSafety/ucm379554.htm on 27 March
  • 2015
VIEW 2 EXCERPTS

Thrombosis in myeloproliferative neoplasms.

  • Seminars in thrombosis and hemostasis
  • 2014
VIEW 1 EXCERPT

Similar Papers

Loading similar papers…